Amalgamated Bank Sells 1,769 Shares of Repligen Co. (NASDAQ:RGEN)

Amalgamated Bank cut its position in shares of Repligen Co. (NASDAQ:RGEN) by 4.9% during the fourth quarter, HoldingsChannel.com reports. The firm owned 34,355 shares of the biotechnology company’s stock after selling 1,769 shares during the period. Amalgamated Bank’s holdings in Repligen were worth $6,177,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also modified their holdings of the company. Raymond James & Associates grew its stake in shares of Repligen by 3.5% in the 3rd quarter. Raymond James & Associates now owns 67,219 shares of the biotechnology company’s stock valued at $10,688,000 after purchasing an additional 2,283 shares during the period. Bank of New York Mellon Corp grew its position in Repligen by 13.0% in the third quarter. Bank of New York Mellon Corp now owns 1,195,629 shares of the biotechnology company’s stock valued at $190,117,000 after acquiring an additional 137,220 shares during the period. Forsta AP Fonden acquired a new position in Repligen during the third quarter worth $1,908,000. Verdence Capital Advisors LLC lifted its holdings in shares of Repligen by 6.7% during the third quarter. Verdence Capital Advisors LLC now owns 2,163 shares of the biotechnology company’s stock valued at $344,000 after acquiring an additional 135 shares during the period. Finally, Keeler THomas Management LLC acquired a new stake in shares of Repligen in the 3rd quarter valued at $428,000. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Repligen

In related news, COO James Bylund sold 4,373 shares of the stock in a transaction that occurred on Friday, February 23rd. The shares were sold at an average price of $198.08, for a total value of $866,203.84. Following the sale, the chief operating officer now directly owns 14,135 shares in the company, valued at approximately $2,799,860.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Repligen news, COO James Bylund sold 4,373 shares of the company’s stock in a transaction that occurred on Friday, February 23rd. The shares were sold at an average price of $198.08, for a total value of $866,203.84. Following the completion of the sale, the chief operating officer now owns 14,135 shares of the company’s stock, valued at $2,799,860.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Anthony Hunt sold 16,707 shares of Repligen stock in a transaction on Friday, March 8th. The stock was sold at an average price of $197.44, for a total transaction of $3,298,630.08. Following the transaction, the chief executive officer now directly owns 185,249 shares in the company, valued at $36,575,562.56. The disclosure for this sale can be found here. In the last ninety days, insiders sold 25,597 shares of company stock worth $5,039,532. 1.20% of the stock is currently owned by company insiders.

Repligen Stock Up 0.4 %

Shares of NASDAQ RGEN opened at $167.05 on Monday. Repligen Co. has a 1 year low of $110.45 and a 1 year high of $211.13. The firm’s 50-day moving average is $180.81 and its 200-day moving average is $174.32. The company has a current ratio of 6.35, a quick ratio of 5.24 and a debt-to-equity ratio of 0.26. The firm has a market capitalization of $9.33 billion, a PE ratio of 668.23, a price-to-earnings-growth ratio of 5.58 and a beta of 1.03.

Repligen (NASDAQ:RGEN) last released its earnings results on Wednesday, May 1st. The biotechnology company reported $0.28 EPS for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.01). Repligen had a return on equity of 3.95% and a net margin of 2.44%. The business had revenue of $151.31 million for the quarter, compared to analyst estimates of $150.06 million. During the same period in the prior year, the firm posted $0.64 EPS. Repligen’s revenue was down 17.1% on a year-over-year basis. Equities analysts expect that Repligen Co. will post 1.46 EPS for the current year.

Analyst Upgrades and Downgrades

RGEN has been the subject of several analyst reports. JPMorgan Chase & Co. cut their price target on shares of Repligen from $230.00 to $200.00 and set an “overweight” rating for the company in a report on Thursday. KeyCorp boosted their target price on Repligen from $210.00 to $220.00 and gave the stock an “overweight” rating in a report on Thursday, February 15th. Finally, Stifel Nicolaus lifted their price objective on Repligen from $165.00 to $207.00 and gave the company a “buy” rating in a research report on Thursday, February 22nd. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $197.75.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.